FDA approves Avycaz for hospital-acquired and ventilator-associated bacterial pneumonias Feb. 2, 2018
UCB announces launch of Syndesi Therapeutics to develop therapeutics for cognitive disorders Feb. 2, 2018
Pfizer enrolling patients in phase II study of PF-06823859 in moderate to severe dermatomyositis Feb. 2, 2018